Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Cash (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Change in Cash for 10 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 139.34% year-over-year to $8.0 million, compared with a TTM value of $28.6 million through Dec 2025, up 408.95%, and an annual FY2025 reading of $28.6 million, up 408.95% over the prior year.
  • Change in Cash was $8.0 million for Q4 2025 at Zevra Therapeutics, up from $6.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $71.7 million in Q1 2021 and bottomed at -$25.3 million in Q1 2023.
  • Average Change in Cash over 5 years is $2.9 million, with a median of -$506000.0 recorded in 2021.
  • The sharpest move saw Change in Cash surged 7178.38% in 2021, then tumbled 9106.36% in 2024.
  • Year by year, Change in Cash stood at -$19.2 million in 2021, then surged by 75.67% to -$4.7 million in 2022, then soared by 95.28% to -$220000.0 in 2023, then crashed by 9106.36% to -$20.3 million in 2024, then skyrocketed by 139.34% to $8.0 million in 2025.
  • Business Quant data shows Change in Cash for ZVRA at $8.0 million in Q4 2025, $6.7 million in Q3 2025, and $10.4 million in Q2 2025.